• Ziprasidone Augmentation in Anxious Depression: Insights & L

  2026-06-03

  This article reviews a post-hoc analysis examining the effects of ziprasidone augmentation in escitalopram-treated patients with anxious versus nonanxious depression. The findings clarify that ziprasidone provides similar antidepressant efficacy regardless of anxiety status, with only modest anxiolytic effects observed.

• Berberine Modulates RXRα/PPARγ/NEDD4 to Suppress SASP in Ath

  2026-06-03

  The referenced study reveals that berberine attenuates senescence-associated secretory phenotype (SASP)-driven inflammation in atherosclerosis by activating the RXRα/PPARγ/NEDD4 pathway in macrophage-derived foam cells. These mechanistic insights clarify how modulation of this axis reduces vascular inflammation, offering researchers new experimental strategies for investigating age-related cardiovascular disease.

• Clozapine N-oxide (CNO): Chemogenetic Precision in Alzheimer

  2026-06-02

  Explore the advanced use of Clozapine N-oxide (CNO) in dissecting neuronal activity in Alzheimer’s disease models. This article delivers a unique synthesis of chemogenetic technology and groundbreaking circuit neuroscience, positioning CNO as an indispensable neuroscience research tool.

• Isradipine (Dynacirc): Applied Workflows in Neuroprotection

  2026-06-02

  Isradipine (Dynacirc) stands out as a selective L-type calcium channel blocker supporting both cardiovascular and neuroprotective research. This article details precise experimental workflows, troubleshooting tips, and highlights from recent channel classification studies, empowering researchers to maximize data reliability and mechanistic clarity.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Proteasome Inhibition in Sign

  2026-06-01

  Explore the advanced use of MG-262 (Z-Leu-Leu-Leu-B(OH)2) in dissecting proteasome-mediated regulation of apoptosis and inflammatory signaling. This article uniquely bridges molecular mechanism with assay optimization, leveraging new insights for targeted research applications.

• CLCC1 Identified as Key Host Factor in Herpesvirus Nuclear E

  2026-06-01

  The reference study uncovers CLCC1 as a critical host protein mediating membrane fusion during herpesvirus nuclear egress, resolving a longstanding gap in understanding how viral capsids exit the nucleus. This discovery has broad implications for virology and nuclear envelope biology, potentially informing future antiviral strategies.

• Sumatriptan Succinate in Translational Migraine Research

  2026-05-31

  Explore the advanced mechanisms and translational potential of Sumatriptan Succinate as a 5-HT1 receptor agonist for migraine and inflammation research. This in-depth review uniquely connects pediatric clinical findings to preclinical assay design, expanding research strategies for serotonergic signaling.

• Cyclophosphamide: Benchmarks, Mechanisms, and Protocol Insig

  2026-05-30

  Cyclophosphamide is a widely used alkylating chemotherapeutic agent with validated activity in cancer and immunology research. Its efficacy stems from DNA cross-linking and potent immunosuppressive mechanisms, supported by robust clinical and preclinical data. APExBIO supplies Cyclophosphamide (A2343) with stringent quality control for reproducible research outcomes.

• Zolmitriptan: 5-HT1B Receptor Agonist Workflows in Migraine

  2026-05-29

  Zolmitriptan, a potent 5-HT1B receptor agonist, enables precise migraine and cluster headache research through validated, reproducible workflows. Explore advanced experimental protocols, real-world troubleshooting, and the translational advantages of APExBIO's high-purity Zolmitriptan.

• Acute Bright Light Triggers Prolonged Anxiety via ipRGC–CeA

  2026-05-29

  The referenced study reveals that brief exposure to bright light induces sustained anxiety-like behaviors in mice, mediated by a melanopsin-based retinal ganglion cell pathway projecting to the central amygdala. This work establishes a non-image forming visual circuit for delayed anxiety extinction, with implications for understanding light’s neuropsychiatric impacts.

• CP-673451 in ATRX-Deficient Glioma: PDGFR Inhibition Redefin

  2026-05-28

  Explore how CP-673451, a selective PDGFRα/β inhibitor, enables advanced cancer research by targeting ATRX-deficient glioma models. This article provides a detailed mechanistic analysis and practical assay insights beyond standard application guides.

• Fangchinoline Restores Lysosomal Biogenesis to Counter H1N1

  2026-05-28

  This study identifies fangchinoline as a lysosome-targeting compound that restores TFEB-driven lysosomal biogenesis, disrupting influenza A (H1N1) infection by counteracting viral strategies that impair lysosomal function. The findings underscore the therapeutic promise of modulating lysosomal pathways in antiviral research and open avenues for integrating lysosomal biology insights in related pharmacological studies.

• Biotin-tyramide: Precision Signal Amplification for IHC & IS

  2026-05-27

  Biotin-tyramide unlocks ultra-sensitive detection in immunohistochemistry and in situ hybridization by leveraging enzyme-mediated signal amplification. This guide details practical workflows, protocol parameters, and advanced troubleshooting to help researchers maximize specificity and signal strength in spatial biology assays.

• WAY-100635: Optimizing 5-HT1A Antagonism in Neuroscience Res

  2026-05-27

  WAY-100635 delivers unmatched selectivity for serotonin 5-HT1A antagonism, empowering researchers to dissect complex neuropharmacological circuits with confidence. This guide translates recent breakthroughs—especially those bridging serotonergic and cannabinoid pathways—into actionable workflows, troubleshooting strategies, and protocol enhancements for advanced neuroscience and behavioral pharmacology.

• Cefiderocol’s In Vitro Efficacy Against Resistant Enterobact

  2026-05-26

  Santerre Henriksen et al. present a pivotal analysis of cefiderocol’s in vitro activity against a broad cohort of European Enterobacterales, including isolates resistant to both meropenem and recently approved β-lactam/β-lactamase inhibitor combinations. The findings highlight cefiderocol’s superior or comparable efficacy, offering critical guidance for antimicrobial stewardship and future research on multidrug-resistant Gram-negative infections.

15723 records 1/1049 page Next 12345 下5页 Last page